Products
Reflocibart Biosimilar Monoclonal Antibody (VEGF-B) for Research
Cat No.: GMP-Bios-INN-1360
Anti-VEGFB therapeutic antibody (Pre-made Reflocibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Reflocibart (development codes CSL-346/2H10) is a humanized monoclonal antibody targeting VEGF-B (VEGFB). It is developed by CSL and Zenyth Therapeutics for Type 2 diabetes mellitus, Cancer, Rheumatoid arthritis et al. in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1360-1mg | 1mg | 3090 |
| GMP-Bios-INN-1360-10mg | 10mg | |
| GMP-Bios-INN-1360-100mg | 100mg | |
| GMP-Bios-INN-1360-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Reflocibart biosimilar, Whole mAb, Anti-VEGFB Antibody: Anti-VEGFB/Vascular endothelial growth factor B/VEGF-B/VEGF-related factor (VRF) therapeutic antibody |
| INN Name | Reflocibart |
| Target | VEGFB |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | CSL;Zenyth Therapeutics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Type 2 diabetes mellitus;Cancer;Rheumatoid arthritis;Diabetic nephropathies |
| Production | na |
| Development Tech | na |
